NDC 0186-0777

BRILINTA

Ticagrelor

BRILINTA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Ticagrelor.

Product ID0186-0777_0127d327-2b47-41ce-b603-4ddc0fc7cca8
NDC0186-0777
Product TypeHuman Prescription Drug
Proprietary NameBRILINTA
Generic NameTicagrelor
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2011-08-05
Marketing CategoryNDA / NDA
Application NumberNDA022433
Labeler NameAstraZeneca Pharmaceuticals LP
Substance NameTICAGRELOR
Active Ingredient Strength90 mg/1
Pharm ClassesP2Y12 Platelet Inhibitor [EPC],Phenylalanine Hydroxylase Activators [MoA],Decreased Platelet Aggregation [PE],P2Y12 Receptor Antagonists [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A5 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 0186-0777-08

8 TABLET in 1 BOTTLE (0186-0777-08)
Marketing Start Date2011-08-05
NDC Exclude FlagN
Sample Package?Y

NDC SPL Data Element Entries

NDC 0186-0777-60 [00186077760]

BRILINTA TABLET
Marketing CategoryNDA
Application NumberNDA022433
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2011-08-05

NDC 0186-0777-18 [00186077718]

BRILINTA TABLET
Marketing CategoryNDA
Application NumberNDA022433
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2011-08-05
Marketing End Date2011-08-05

NDC 0186-0777-08 [00186077708]

BRILINTA TABLET
Marketing CategoryNDA
Application NumberNDA022433
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2011-08-05

NDC 0186-0777-39 [00186077739]

BRILINTA TABLET
Marketing CategoryNDA
Application NumberNDA022433
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2011-08-05

NDC 0186-0777-28 [00186077728]

BRILINTA TABLET
Marketing CategoryNDA
Application NumberNDA022433
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2011-08-05
Marketing End Date2017-04-28

Drug Details

Active Ingredients

IngredientStrength
TICAGRELOR90 mg/1

Pharmacological Class

  • P2Y12 Platelet Inhibitor [EPC]
  • Phenylalanine Hydroxylase Activators [MoA]
  • Decreased Platelet Aggregation [PE]
  • P2Y12 Receptor Antagonists [MoA]
  • Cytochrome P450 3A4 Inhibitors [MoA]
  • Cytochrome P450 3A5 Inhibitors [MoA]
  • P-Glycoprotein Inhibitors [MoA]

NDC Crossover Matching brand name "BRILINTA" or generic name "Ticagrelor"

NDCBrand NameGeneric Name
0186-0776BRILINTATicagrelor
0186-0777BRILINTATicagrelor
55154-9618BRILINTATicagrelor
69238-1134ticagrelorticagrelor

Trademark Results [BRILINTA]

Mark Image

Registration | Serial
Company
Trademark
Application Date
BRILINTA
BRILINTA
78457162 3040606 Live/Registered
AstraZeneca AB
2004-07-27

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.